$KPTI
Karyopharm Therapeutics Inc.

2022 Q3 Form 10-Q Financial Statement

#000095017022014788 Filed on August 04, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1
Revenue $36.15M $39.68M $47.67M
YoY Change -4.1% 75.56% 104.94%
Cost Of Revenue $980.0K $939.0K $1.426M
YoY Change 66.38% -17.49% 53.33%
Gross Profit $35.17M $38.74M $46.24M
YoY Change -5.22% 80.5% 107.09%
Gross Profit Margin 97.29% 97.63% 97.01%
Selling, General & Admin $34.65M $37.34M $38.77M
YoY Change -1.31% 2.21% 2.97%
% of Gross Profit 98.52% 96.38% 83.83%
Research & Development $31.36M $44.31M $42.06M
YoY Change -31.54% 30.39% 13.53%
% of Gross Profit 89.18% 114.38% 90.96%
Depreciation & Amortization $182.0K $149.0K $177.0K
YoY Change -2.15% -33.48% -24.68%
% of Gross Profit 0.52% 0.38% 0.38%
Operating Expenses $66.00M $82.59M $82.26M
YoY Change -19.01% 15.27% 8.76%
Operating Profit -$30.84M -$42.91M -$34.59M
YoY Change -29.61% -12.52% -33.96%
Interest Expense -$5.456M $6.313M $6.684M
YoY Change -168.11% 26.23% 31.19%
% of Operating Profit
Other Income/Expense, Net $16.00K -$6.033M -$6.683M
YoY Change -100.2% 37.11% 36.61%
Pretax Income -$36.28M -$48.94M -$41.27M
YoY Change -29.84% -8.43% -27.93%
Income Tax $45.00K $121.0K $130.0K
% Of Pretax Income
Net Earnings -$36.32M -$49.06M -$41.40M
YoY Change -29.89% -8.44% -27.89%
Net Earnings / Revenue -100.5% -123.65% -86.84%
Basic Earnings Per Share -$0.45 -$0.62 -$0.53
Diluted Earnings Per Share -$452.9K -$0.62 -$533.7K
COMMON SHARES
Basic Shares Outstanding 79.81M 79.65M 79.16M
Diluted Shares Outstanding 80.21M 79.65M 77.57M

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $148.4M $170.8M $205.3M
YoY Change -27.34% -27.57% -8.49%
Cash & Equivalents $71.35M $82.25M $153.3M
Short-Term Investments $77.03M $88.60M $52.06M
Other Short-Term Assets $42.60M $32.08M $29.14M
YoY Change 190.36% 102.77% 185.64%
Inventory $4.249M $3.470M $3.874M
Prepaid Expenses $11.43M $12.21M
Receivables $27.45M $23.48M $24.99M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $222.7M $242.4M $276.5M
YoY Change -7.82% -11.35% 8.23%
LONG-TERM ASSETS
Property, Plant & Equipment $7.933M $1.395M $1.544M
YoY Change 404.0% -20.51% -22.18%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $626.0K $5.529M $8.438M
YoY Change -2.03% 765.26% 1105.43%
Total Long-Term Assets $8.559M $14.03M $17.50M
YoY Change -31.61% 7.39% -9.78%
TOTAL ASSETS
Total Short-Term Assets $222.7M $242.4M $276.5M
Total Long-Term Assets $8.559M $14.03M $17.50M
Total Assets $231.2M $256.5M $294.0M
YoY Change -9.0% -10.5% 6.96%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $813.0K $1.694M $3.440M
YoY Change -7.72% -26.63% 13.16%
Accrued Expenses $58.49M $56.37M $58.37M
YoY Change -9.6% 5.93% 4.96%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $61.76M $62.54M $66.34M
YoY Change -10.32% 7.6% 6.98%
LONG-TERM LIABILITIES
Long-Term Debt $302.9M $302.7M $302.5M
YoY Change 0.44% 0.44% 25.1%
Other Long-Term Liabilities $6.863M $7.584M $8.286M
YoY Change -28.76% -25.64% -22.56%
Total Long-Term Liabilities $309.8M $310.3M $310.8M
YoY Change -0.47% -0.42% 23.08%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.76M $62.54M $66.34M
Total Long-Term Liabilities $309.8M $310.3M $310.8M
Total Liabilities $371.5M $372.8M $377.1M
YoY Change -2.25% 0.84% 19.89%
SHAREHOLDERS EQUITY
Retained Earnings -$1.269B -$1.220B
YoY Change 8.88% 9.72%
Common Stock $1.153B $1.137B
YoY Change 6.57% 6.05%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$140.3M -$116.3M -$83.08M
YoY Change
Total Liabilities & Shareholders Equity $231.2M $256.5M $294.0M
YoY Change -9.0% -10.5% 6.96%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1
OPERATING ACTIVITIES
Net Income -$36.32M -$49.06M -$41.40M
YoY Change -29.89% -8.44% -27.89%
Depreciation, Depletion And Amortization $182.0K $149.0K $177.0K
YoY Change -2.15% -33.48% -24.68%
Cash From Operating Activities -$28.37M -$35.14M -$59.20M
YoY Change 18.43% -36.96% 11.93%
INVESTING ACTIVITIES
Capital Expenditures -$39.00K $0.00 $79.00K
YoY Change 680.0%
Acquisitions
YoY Change
Other Investing Activities $11.71M -$36.60M -$13.96M
YoY Change -45.35% -178.78% -132.31%
Cash From Investing Activities $11.67M -$36.60M -$14.04M
YoY Change -45.52% -178.78% -132.5%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.799M 1.313M 30.78M
YoY Change 36143.75% -97.88% 188.34%
NET CHANGE
Cash From Operating Activities -28.37M -35.14M -59.20M
Cash From Investing Activities 11.67M -36.60M -14.04M
Cash From Financing Activities 5.799M 1.313M 30.78M
Net Change In Cash -10.90M -70.43M -42.54M
YoY Change 333.66% -233.48% -4917.55%
FREE CASH FLOW
Cash From Operating Activities -$28.37M -$35.14M -$59.20M
Capital Expenditures -$39.00K $0.00 $79.00K
Free Cash Flow -$28.33M -$35.14M -$59.28M
YoY Change 18.29% -36.96% 12.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
kpti Other Royalty Revenue
OtherRoyaltyRevenue
1900000
dei Entity Central Index Key
EntityCentralIndexKey
0001503802
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36167
dei Entity Registrant Name
EntityRegistrantName
Karyopharm Therapeutics Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-3931704
dei Entity Address Address Line1
EntityAddressAddressLine1
85 Wells Avenue, 2nd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
Newton
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02459
dei City Area Code
CityAreaCode
617
dei Local Phone Number
LocalPhoneNumber
658-0600
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
KPTI
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1642000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7107000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
7915000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
275606000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1395000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
8969000
CY2022Q2 us-gaap Liabilities
Liabilities
372816000
CY2021Q4 us-gaap Liabilities
Liabilities
384978000
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
79806616
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82248000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
190459000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
88598000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
38156000
CY2022Q2 us-gaap Receivables Net Current
ReceivablesNetCurrent
23479000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
22497000
CY2022Q2 us-gaap Inventory Net
InventoryNet
3470000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4106000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
11428000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
12511000
CY2022Q2 us-gaap Other Assets Current
OtherAssetsCurrent
32078000
CY2021Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1528000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1146000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6349000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
242447000
CY2022Q2 us-gaap Other Assets
OtherAssets
4898000
CY2021Q4 us-gaap Other Assets
OtherAssets
19505000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
631000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
637000
CY2022Q2 us-gaap Assets
Assets
256478000
CY2021Q4 us-gaap Assets
Assets
305305000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
1694000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1603000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
56367000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
69121000
CY2022Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2615000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2316000
CY2022Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1865000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
678000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
62541000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
73718000
CY2022Q2 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
169693000
CY2021Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
169293000
CY2022Q2 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132998000
CY2021Q4 kpti Deferred Royalty Obligation Noncurrent
DeferredRoyaltyObligationNoncurrent
132998000
CY2022Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7584000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
us-gaap Operating Income Loss
OperatingIncomeLoss
-101421000
CY2022Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1153301000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1098776000
CY2022Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-538000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
191000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1269109000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1178648000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-116338000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
293000
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
165000
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
79798000
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
79798000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
75746000
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
75746000
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
256478000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
305305000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
39679000
CY2021Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
22601000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
87349000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
45861000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44309000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33981000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
86371000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71031000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
37339000
CY2021Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
36530000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
76107000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
74180000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
82587000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
71649000
us-gaap Operating Expenses
OperatingExpenses
164843000
us-gaap Operating Expenses
OperatingExpenses
147282000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-42908000
CY2021Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-49048000
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.15
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.15
us-gaap Investment Income Interest
InvestmentIncomeInterest
367000
us-gaap Investment Income Interest
InvestmentIncomeInterest
429000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.48
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.48
us-gaap Operating Income Loss
OperatingIncomeLoss
-77494000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79651000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79651000
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
75189000
CY2022Q2 us-gaap Interest Expense
InterestExpense
6313000
CY2021Q2 us-gaap Interest Expense
InterestExpense
5001000
us-gaap Interest Expense
InterestExpense
12997000
us-gaap Interest Expense
InterestExpense
10096000
CY2022Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-53448000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-90210000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-110713000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
121000
CY2021Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
134000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
251000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
283000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49062000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-53582000
us-gaap Net Income Loss
NetIncomeLoss
-90461000
us-gaap Net Income Loss
NetIncomeLoss
-110996000
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.62
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.62
CY2021Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
436000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-86000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
375000
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-6033000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4400000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-12716000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9292000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-48941000
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
75189000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
78616000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
78616000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
74863000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
74863000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49062000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-53582000
us-gaap Net Income Loss
NetIncomeLoss
-90461000
us-gaap Net Income Loss
NetIncomeLoss
-110996000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-170000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-41000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-184000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-173000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-455000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-64000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-545000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-149000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-94341000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-49687000
CY2021Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-53687000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-91190000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-111318000
us-gaap Profit Loss
ProfitLoss
-90461000
us-gaap Profit Loss
ProfitLoss
-110996000
us-gaap Depreciation
Depreciation
326000
us-gaap Depreciation
Depreciation
464000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
71000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1148000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
400000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
386000
us-gaap Share Based Compensation
ShareBasedCompensation
22429000
us-gaap Share Based Compensation
ShareBasedCompensation
15494000
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
0
us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
610000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
4000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-231000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
982000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
5006000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-636000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1506000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
14860000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
5773000
kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-808000
kpti Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-698000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
91000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2141000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-11567000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
196000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-297000
kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1086000
kpti Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-924000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-108636000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
79000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
48468000
us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
124376000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
99020000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
34732000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-50631000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
89644000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
29294000
kpti Proceeds From Payments For Common Stock Issuance Net
ProceedsFromPaymentsForCommonStockIssuanceNet
9903000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2802000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
2833000
kpti Proceeds From Amended Revenue Interest Agreement
ProceedsFromAmendedRevenueInterestAgreement
0
kpti Proceeds From Amended Revenue Interest Agreement
ProceedsFromAmendedRevenueInterestAgreement
60000000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32096000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72736000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-544000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-155000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-113420000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
53589000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
197445000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-83132000
kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
30039000
kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
3951000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89121000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84025000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142710000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
82248000
CY2021Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
141309000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
1146000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
762000
CY2022Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
631000
CY2021Q2 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
639000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84025000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
142710000
us-gaap Interest Paid Net
InterestPaidNet
2588000
us-gaap Interest Paid Net
InterestPaidNet
2588000
kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1682000
kpti Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1630000
us-gaap Payments For Royalties
PaymentsForRoyalties
20746000
us-gaap Payments For Royalties
PaymentsForRoyalties
4068000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-83079000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1335000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15093000
CY2022Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-170000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-455000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-49062000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-116338000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-39640000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2060000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8135000
CY2021Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-41000
CY2021Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-64000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-53582000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-83132000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-79673000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2802000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22429000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
29294000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-184000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-545000
us-gaap Net Income Loss
NetIncomeLoss
-90461000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-116338000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
50546000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2833000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
15494000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
9903000
kpti Cumulative Effect Adjustment For Adoption Of New Accounting Guidance
CumulativeEffectAdjustmentForAdoptionOfNewAccountingGuidance
-50590000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-173000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-149000
us-gaap Net Income Loss
NetIncomeLoss
-110996000
CY2022Q2 kpti Other Royalty Revenue
OtherRoyaltyRevenue
1600000
CY2022Q2 kpti Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
1500000
CY2021Q2 kpti Other Royalty Revenue
OtherRoyaltyRevenue
1300000
CY2021Q2 kpti Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
1000000.0
kpti Other Royalty Revenue
OtherRoyaltyRevenue
4100000
kpti Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
2300000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
0
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2022Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
261000
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1797000
CY2022Q2 us-gaap Inventory Work In Process
InventoryWorkInProcess
2866000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
1895000
CY2022Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
343000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
414000
CY2022Q2 us-gaap Inventory Net
InventoryNet
3470000
CY2021Q4 us-gaap Inventory Net
InventoryNet
4106000
CY2022Q2 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
10669000
CY2021Q2 kpti Contract With Customer License And Other Revenue
ContractWithCustomerLicenseAndOtherRevenue
2422000
kpti Milestone Method Revenue Recognized
MilestoneMethodRevenueRecognized
1500000
CY2022Q2 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
125308000
CY2022Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3080000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
95101000
CY2021Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3080000
CY2022Q2 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
88784000
us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
0
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
186000
CY2022Q2 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
88598000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
38161000
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Gain
AvailableForSaleDebtSecuritiesGrossUnrealizedGain
4000
CY2021 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
9000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
38156000
CY2022Q2 kpti Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax Other Than Temporary Impairments
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxOtherThanTemporaryImpairments
0
CY2022Q2 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
37
CY2021Q4 kpti Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Years
AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYears
37
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
86603000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
186000
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022Q2 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
0
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
86603000
CY2022Q2 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
186000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
26650000
CY2021Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position Less Than12 Months Accumulated Loss
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
9000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
26650000
CY2021Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position Accumulated Loss
DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
9000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15093000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8135000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22429000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15494000
kpti Debt Instrument Convertible Threshold Measurement Period Description
DebtInstrumentConvertibleThresholdMeasurementPeriodDescription
during the five business day period immediately after any five consecutive trading day period
kpti Principal Amount Of Notes Used In Conversion Rate
PrincipalAmountOfNotesUsedInConversionRate
1000
kpti Debt Instrument Convertible Threshold Maximum Percentage Of Product Of Last Reported Sale Price Of Common Stock
DebtInstrumentConvertibleThresholdMaximumPercentageOfProductOfLastReportedSalePriceOfCommonStock
0.98
us-gaap Debt Instrument Convertible Threshold Consecutive Trading Days1
DebtInstrumentConvertibleThresholdConsecutiveTradingDays1
5
CY2022Q2 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3100000
CY2021Q4 us-gaap Embedded Derivative Fair Value Of Embedded Derivative Liability
EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
3100000

Files In Submission

Name View Source Status
0000950170-22-014788-index-headers.html Edgar Link pending
0000950170-22-014788-index.html Edgar Link pending
0000950170-22-014788.txt Edgar Link pending
0000950170-22-014788-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
kpti-20220630.htm Edgar Link pending
kpti-20220630.xsd Edgar Link pending
kpti-20220630_cal.xml Edgar Link unprocessable
kpti-20220630_def.xml Edgar Link unprocessable
kpti-20220630_htm.xml Edgar Link completed
kpti-20220630_lab.xml Edgar Link unprocessable
kpti-20220630_pre.xml Edgar Link unprocessable
kpti-ex10_2.htm Edgar Link pending
kpti-ex10_3.htm Edgar Link pending
kpti-ex10_4.htm Edgar Link pending
kpti-ex10_5.htm Edgar Link pending
kpti-ex10_7.htm Edgar Link pending
kpti-ex10_8.htm Edgar Link pending
kpti-ex10_9.htm Edgar Link pending
kpti-ex31_1.htm Edgar Link pending
kpti-ex31_2.htm Edgar Link pending
kpti-ex32_1.htm Edgar Link pending
kpti-ex32_2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending